Format

Send to

Choose Destination
Eye (Lond). 2007 Jun;21(6):824-5. Epub 2006 Apr 7.

Adalimumab for sight-threatening uveitis in Behçet's disease.

Author information

1
Birmingham and Midland Eye Centre, Birmingham, UK.

Abstract

AIMS:

To describe the clinical outcome of three patients with Behçet's disease maintained on infliximab who were switched to adalimumab therapy.

METHODS:

Case note review. Main outcome measure was recurrence of uveitis.

RESULTS:

All patients remained free of recurrence with stable visual acuities.

CONCLUSIONS:

Adalimumab appears to maintain disease remission in Behçet's disease.

PMID:
16601736
DOI:
10.1038/sj.eye.6702352
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center